TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of triple combination
antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and
to gain data on the effectiveness of TCAD